Detalhe da pesquisa
1.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
2.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
3.
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Eur J Haematol
; 110(6): 626-632, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752328
4.
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Eur J Haematol
; 111(3): 373-381, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311695
5.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination.
Eur J Haematol
; 109(5): 458-464, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810359
6.
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.
BMC Cancer
; 21(1): 1207, 2021 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34772368
7.
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Eur J Haematol
; 107(6): 602-608, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378251
8.
Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.
J Clin Apher
; 36(4): 553-562, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33710672
9.
Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
J Oncol Pharm Pract
; 26(5): 1128-1133, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31795821
10.
A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant.
Biol Blood Marrow Transplant
; 25(10): e305-e309, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31295572
11.
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(3): 459-465, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30481597
12.
Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
J Oncol Pharm Pract
; 23(3): 215-219, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26811403
13.
Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.
BMC Cancer
; 21(1): 1291, 2021 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34856934
14.
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Br J Haematol
; 186(1): 140-144, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536372
15.
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood
; 120(8): 1597-600, 2012 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22674807
16.
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
Life (Basel)
; 14(3)2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38541708
17.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Blood Adv
; 8(1): 251-259, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855718
18.
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Transplant Cell Ther
; 29(4): 262.e1-262.e6, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682468
19.
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.
J Hematol
; 12(1): 1-6, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895290
20.
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.
Cancers (Basel)
; 15(11)2023 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296856